Board Strength Burst Diagnostics recently expanded governance with new board members including Drs. Larry Jia and Mary Gunn, signaling growth potential and credibility. Leverage executive engagement to open strategic conversations around partnerships, funding rounds, and scalable manufacturing collaborations.

Home and Point-of-Care Focus The company specializes in at-home and point-of-care diagnostics with a rapid, low-cost immunoassay platform. This presents sales opportunities for distribution partnerships, consumables, and integration into mobile testing kits or clinic-based point-of-need workflows.

Custom Assay Capabilities Burst offers custom assay development services powered by the CaDI platform. Target labs, clinics, and manufacturers needing tailored analytes or sample types may benefit from a joint development and manufacturing agreement, expanding contract manufacturing and CRO collaborations.

Early Revenue Trajectory With revenue in the low to mid single digits and total funding of around $2.7M, Burst is in an early-growth phase. This indicates potential for strategic partnerships, pilot programs, and phased deployments to demonstrate value and drive larger enterprise deals.

Small-Team Agility An 11-50 employee base suggests nimble operations and rapid iteration. This is favorable for vendor integrations, fast-tracked pilots, and flexible collaboration on product enhancements, regulatory support, and manufacturing scale-up.